Index/Organizations/Society of Urologic Oncology

Society of Urologic Oncology

Organization in Schaumburg, United States

Fact-Checks

11 results
Jan 19, 2026
Most Viewed

How should PSA kinetics and PSMA PET findings be integrated with margin and Gleason data when planning salvage radiation?

Salvage radiotherapy (sRT) planning should synthesize PSA kinetics (especially PSA doubling time), PSMA-PET findings, pathologic Gleason Grade Group, and margin status to stratify risk, decide on targ...

Nov 26, 2025
Most Viewed

How do different PSA thresholds (detectable, 0.2 ng/mL, rising doubling time) influence salvage radiotherapy outcomes?

Salvage radiotherapy (SRT) works best when PSA is low: multiple guideline reviews and cohort studies show improved biochemical-relapse–free and metastasis-free survival when SRT is given at lower PSA ...

Jan 22, 2026

How should management (staging, systemic therapy, trials) change for patients with high‑grade prostate cancer and very low PSA?

(Grade Group 4–5 or Gleason ≥8) with a deceptively low serum PSA should trigger more aggressive staging and consideration of treatment intensification rather than reassurance; modern imaging (includin...

Dec 12, 2025

What PSA threshold after prostatectomy indicates need for salvage radiation?

Guidelines and large studies do not set a single PSA “trigger” after radical prostatectomy; contemporary recommendations commonly consider salvage radiation once PSA is detectable and rising, with thr...

Dec 12, 2025

When is adjuvant or salvage radiation recommended based on rising PSA after prostatectomy?

After radical prostatectomy (RP), the American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology (AUA/ASTRO/SUO) 2024–25 guidance advises offering salvage rad...

Dec 3, 2025

How do PSA doubling time and velocity influence timing of salvage therapy?

PSA doubling time (PSADT) and PSA velocity (PSAV) are established prognostic markers used to time salvage therapy: short PSADT — commonly <6–12 months — signals higher risk of metastasis and is cited ...

Dec 3, 2025

What imaging should be done to localize recurrence before salvage radiation therapy?

Current expert guidance recommends next‑generation molecular PET—preferably PSMA‑PET—plus pelvic MRI when evaluating suspected recurrence before offering curative‑intent salvage radiation therapy; gui...

Nov 17, 2025

When is salvage radiation therapy indicated versus systemic hormone therapy for biochemical relapse?

Salvage radiotherapy (SRT) is the primary potentially curative option for biochemical recurrence after radical prostatectomy and is often recommended early when PSA is low; randomized trials (GETUG‑AF...

Nov 15, 2025

How do PSA thresholds and kinetics guide timing decisions for salvage radiotherapy?

Guidance and studies converge on one principle: earlier salvage radiotherapy (SRT) after radical prostatectomy—when PSA is low—is associated with better biochemical control, metastasis‑free outcomes a...

Nov 15, 2025

How does timing of salvage radiotherapy affect long-term cancer control and toxicity?

Early initiation of salvage radiotherapy (SRT) at low prostate‑specific antigen (PSA) levels is consistently associated with better long‑term oncologic control—studies and guidelines report improved b...

Nov 15, 2025

When is salvage radiation therapy indicated for post-prostatectomy biochemical recurrence?

Salvage radiation therapy (SRT) is the primary curative local option for men with biochemical recurrence (BCR) after radical prostatectomy; guidelines define BCR as PSA ≥0.2 ng/mL confirmed and recomm...